Health care leaders are concerned about the growing problem of drug shortages linked to manufacturing problems and the rise of what the speakers described as a “gray market,’’ in which drug suppliers stockpile medications, then sell them at inflated prices. David Frank, HMS associate professor of medicine at Dana-Farber Cancer Institute, is quoted.
